{"id":"high-dose-corticosteroid-pulse-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Insomnia and mood disturbances"},{"rate":null,"effect":"Infection (opportunistic)"},{"rate":null,"effect":"Electrolyte abnormalities"},{"rate":null,"effect":"Osteoporosis (with repeated use)"}]},"_chembl":{"chemblId":"CHEMBL664","moleculeType":"Small molecule","molecularWeight":"176.22"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This treatment involves administering supraphysiologic doses of corticosteroids intravenously over short periods to achieve potent immunosuppression and anti-inflammatory effects. The high doses overwhelm immune cell function, reduce cytokine production, and suppress T-cell and B-cell activation more effectively than conventional oral corticosteroid regimens. It is commonly used in acute, severe autoimmune and inflammatory conditions where rapid disease control is critical.","oneSentence":"High-dose corticosteroid pulse therapy delivers large intravenous doses of corticosteroids (typically methylprednisolone) to rapidly suppress immune and inflammatory responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:47:39.970Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Severe autoimmune diseases (e.g., lupus nephritis, vasculitis)"},{"name":"Acute exacerbations of multiple sclerosis"},{"name":"Severe organ rejection in transplantation"},{"name":"Acute severe inflammatory conditions refractory to conventional therapy"}]},"trialDetails":[{"nctId":"NCT07299695","phase":"PHASE3","title":"Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis","status":"RECRUITING","sponsor":"Argyrios Tzouvelekis","startDate":"2026-01-25","conditions":"Idiopathic Pulmonary Fibrosis, Acute Exacerbation of Idiopathic Pulmonary Fibrosis","enrollment":196},{"nctId":"NCT07420296","phase":"PHASE4","title":"Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder","status":"RECRUITING","sponsor":"Tianjin Medical University General Hospital","startDate":"2026-01-01","conditions":"Neuromyelitis Optica Spectrum Disorders (NMOSD)","enrollment":198},{"nctId":"NCT05150704","phase":"PHASE3","title":"MYTHS - MYocarditis THerapy With Steroids","status":"RECRUITING","sponsor":"Niguarda Hospital","startDate":"2021-10-07","conditions":"Myocarditis Acute","enrollment":288},{"nctId":"NCT04662723","phase":"PHASE4","title":"Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.","status":"RECRUITING","sponsor":"Fondazione Schena","startDate":"2023-05-01","conditions":"Glomerulonephritis, Immunoglobulin A Nephropathy","enrollment":878},{"nctId":"NCT05714670","phase":"PHASE2","title":"The Effect of Curcumin on the Clinical Outcome of Pediatric Patients with Active Lupus Nephritis","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-04-01","conditions":"Lupus Nephritis, SLE Nephritis","enrollment":72},{"nctId":"NCT06367517","phase":"","title":"Tocilizumab in Corticosteroid-Resistant Graves' Orbitopathy (Thyroid Eye Disease)","status":"RECRUITING","sponsor":"Medical University of Warsaw","startDate":"2021-05-20","conditions":"Orbitopathy, Graves, Thyroid Eye Disease, Ophthalmopathy","enrollment":30},{"nctId":"NCT05925140","phase":"PHASE1","title":"LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients","status":"UNKNOWN","sponsor":"Lebanese University","startDate":"2020-03-28","conditions":"COVID-19, Hospitalized COVID-19 Patients","enrollment":1000},{"nctId":"NCT03752307","phase":"PHASE1, PHASE2","title":"Safety and Tolerability of ISX (Isoxsuprine HCL) in MS Relapses","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2019-02-15","conditions":"Multiple Sclerosis","enrollment":2},{"nctId":"NCT04239196","phase":"PHASE2","title":"Efficacy of Tocilizumab for the Treatment of Acute AION Related to GCA","status":"UNKNOWN","sponsor":"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","startDate":"2020-09-10","conditions":"Giant Cell Arteritis, Optic Ischaemic Neuropathy","enrollment":58},{"nctId":"NCT05133635","phase":"PHASE4","title":"High-Dose Corticosteroid or Tocilizumab for Clinical Worsening of COVID-19","status":"WITHDRAWN","sponsor":"Marmara University","startDate":"2021-02-01","conditions":"COVID-19 Virus Infection, Cytokine Storm, Corticosteroid","enrollment":""},{"nctId":"NCT04492501","phase":"NA","title":"Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan","status":"COMPLETED","sponsor":"UNICEF","startDate":"2020-04-01","conditions":"Covid19, Cytokine Release Syndrome, Critical Illness","enrollment":600},{"nctId":"NCT00263562","phase":"PHASE3","title":"Steroid Treatment for Sickle Cell Pain Crisis","status":"TERMINATED","sponsor":"Baylor College of Medicine","startDate":"2005-12-01","conditions":"Sickle Cell Disease, Vaso-occlusive Crisis","enrollment":18},{"nctId":"NCT01576718","phase":"PHASE2","title":"A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2012-04","conditions":"Asthma","enrollment":889},{"nctId":"NCT01211665","phase":"PHASE4","title":"Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS)","status":"TERMINATED","sponsor":"Biogen","startDate":"2010-09","conditions":"Immune Reconstitution Inflammatory Syndrome, Leukoencephalopathy, Progressive Multifocal","enrollment":3}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":30,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"High-dose corticosteroid pulse therapy","genericName":"High-dose corticosteroid pulse therapy","companyName":"Tianjin Medical University General Hospital","companyId":"tianjin-medical-university-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"High-dose corticosteroid pulse therapy delivers large intravenous doses of corticosteroids (typically methylprednisolone) to rapidly suppress immune and inflammatory responses. Used for Severe autoimmune diseases (e.g., lupus nephritis, vasculitis), Acute exacerbations of multiple sclerosis, Severe organ rejection in transplantation.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}